IRWD IRONWOOD PHARMACEUTICALS INCcompanySEC Filings & Insider Trading Activity 2026
Latest IRONWOOD PHARMACEUTICALS INC (IRWD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 11, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for IRONWOOD PHARMACEUTICALS INC (IRWD) (SEC CIK 1446847), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • Ironwood confirmed it met liquidity conditions required to lock in the Dec 31, 2028 maturity date on its revolving credit facility
- • Failure to satisfy these conditions would have triggered an earlier maturity — confirmation removes that near-term refinancing risk
Item 2.02: Results of Operations and Financial Condition
- • Q1 2025 earnings press release referenced via exhibit — full financial results contained in the attached exhibit, not in filing body
- • Investors should review Exhibit for key metrics: revenue, EPS, and guidance updates for IRWD's GI-focused portfolio
Recent 8-K FilingsCurrent Reports
AI-powered analysis of IRONWOOD PHARMACEUTICALS INC (IRWD) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 11, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | — | |
8-K | Feb 25, 2026 | — | Analysis | — |
8-K | Jan 2, 2026 | — | — | |
8-K | Dec 23, 2025 | — | — | |
8-K | Nov 26, 2025 | — | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 11, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-K | Mar 31, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Feb 16, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Feb 16, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Feb 18, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 17, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest IRWD SEC filings in 2026?
IRONWOOD PHARMACEUTICALS INC (IRWD) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 11, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did IRWD file its most recent 10-K annual report?
IRONWOOD PHARMACEUTICALS INC (IRWD) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view IRWD 10-Q quarterly reports?
IRONWOOD PHARMACEUTICALS INC (IRWD)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every IRWD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has IRWD filed recently?
IRONWOOD PHARMACEUTICALS INC (IRWD)'s most recent 8-K was filed on March 11, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find IRWD insider trading activity (Form 4)?
SignalX aggregates every IRWD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does IRWD file with the SEC?
IRONWOOD PHARMACEUTICALS INC (IRWD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IRWD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for IRONWOOD PHARMACEUTICALS INC (IRWD).
What is IRWD's SEC CIK number?
IRONWOOD PHARMACEUTICALS INC (IRWD)'s SEC CIK (Central Index Key) number is 1446847. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1446847 to look up all IRWD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find IRWD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from IRONWOOD PHARMACEUTICALS INC (IRWD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of IRONWOOD PHARMACEUTICALS INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 51+ filings.